Call Start: 08:30 January 1, 0000 9:32 AM ET MiMedx Group, Inc. (NASDAQ:MDXG) Q3 2021 Earnings Conference Call November 3, 2021 08:30 ET Company Participants Alexandra Haden - General Counsel & Secretary Tim Wright - Chief Executive Officer Pete Carlson - Chief Financial Officer Rohit Kashyap - Executive Vice President & Chief Commercial Officer Conference Call Participants Carl Byrnes - Northland Capital Markets Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Small Cap Research Eiad Asba ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-2 ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants Jack Howarth - SVP of IR Tim Wright - CEO Pete Carlson - CFO Robert Stein - EVP of R&D Rohit Kashyap - EVP and CCO Conference Call Participants Carl Byrnes - Northland Securities John Vandermosten - Zacks SCR Sean Lee - H.C. Wainwright Eiad Asbahi - Prescience Point Capital Operator Ladies and gentlemen, thank you for standing by. And welcome to MiMedx Second Quarter 2021 Operating and Financial ...

MIMEDX GROUP, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 Securities registered pursuant to Section 12(b) of the Act: | | | Name o ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q1 2021 Earnings Conference Call April 29, 2021 8:30 AM ET Company Participants Alexandra Haden - Former General Counsel & Secretary Tim Wright - Chief Executive Officer Pete Carlson - Chief Financial Officer Rohit Kashyap - Executive VP & Chief Commercial Officer Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright John Vandermosten - Zacks Operator Ladies and gentlemen, thank you for standing by, and welcome to the MiMedx First Quarter 2021 Operating and F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________to______________________ Commission File Number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) Florida 26-27925 ...

| --- | --- | --- | |------------------------------------------------------------|-------------------------------|-------| | | | | | | | | | MiMedx | | | | ADVANCED PLACENTAL SCIENCE March 9-10, 2021 | INNOVATING TREATMENTS THROUGH | | | 2021 H.C. Wainwright & Co. Global Life Sciences Conference | | | IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Actual results may differ materially. Investors are cautioned against placing undue reliance on these statements, All state ...

MiMedx Group, Inc. (NASDAQ:MDXG) Q4 2020 Earnings Conference Call March 8, 2021 9:30 AM ET Company Participants Jack Howarth - VP of IR and Corporate Communications Tim Wright - CEO Pete Carlson - CFO Robert Stein - EVP, Research & Development Rohit Kashyap - EVP and Chief Commercial Officer Conference Call Participants Sean Kang - H.C. Wainwright John Vandermosten - SIC Zacks Eiad Asbahi - Prescience Point Operator Ladies and gentlemen, thank you for standing by, and welcome to the MiMedx Fourth Quarter 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to __________ Commission file number 001-35887 MIMEDX GROUP, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

| --- | --- | --- | |-------------------------------------------------------------------------------|-------|-------| | | | | | INNOVATING TREATMENTS THROUGH ADVANCED PLACENTAL SCIENCE January 11-14, 2021 | | | | 2021 J.P. Morgan 39th Annual Healthcare Conference | | | IMPORTANT CAUTIONARY STATEMENT This presentation contains forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or results that may occur in the future are fo ...